Endometrial adenocarcinoma after prolonged tibolone therapy.
Nassar
A H
AH
Department of Obstetrics and Gynecology, American University of Beirut Medical Center,P. O. Box: 113-6044/B36, Beirut, Lebanon. an21@aub.edu.lb
Khalil
A M
AM
Seoud
M A F
MA
Usta
I M
IM
D000230:Adenocarcinoma / Q000139:chemically induced / Q000150:complications / Q000175:diagnosis* / Q000473:pathology / Q000532:radiotherapy; D001918:Brachytherapy; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000150:complications / Q000175:diagnosis* / Q000473:pathology / Q000532:radiotherapy; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage / Q000009:adverse effects*; D017698:Postmenopause; D014592:Uterine Hemorrhage / Q000209:etiology
D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; C027385:tibolone